Hypoxia-inducible factor 1 in lower limb ischemia.
In the Western world, peripheral vascular disease (PVD) has a high prevalence and is associated with high morbidity and mortality. More patients are presenting with critical limb ischemia (CLI), the end stage of PVD, because of an increased life expectancy owing to improved medical care. In a large percentage of these patients, lower limb amputation is still required, despite current advances in surgery and interventional radiology. Studies of ischemic skeletal muscles disclosed evidence of endogenous angiogenesis and adaptive skeletal muscle metabolic changes in response to hypoxia. Many of the genes responsible for these responses are regulated by hypoxia-inducible factor (HIF)-1. HIF-1, consisting of HIF-1alpha and HIF-1beta subunits, is a major transcription factor that functions as a master regulator of oxygen homeostasis that plays essential roles in cellular and systemic pathophysiology. HIF-1alpha expression and HIF-1 transcriptional activity increase exponentially as cellular oxygen concentration is decreased. More than 60 target genes that are transactivated by HIF-1 have been identified. Many of the target genes, such as vascular endothelial growth factor, have been studied extensively, especially in tumors. However, only recently that interest in HIF-1 is growing in relation to ischemic diseases. Most of the studies concentrated mainly on the angiogenic property of HIF-1. In contrast, there is a lack of information on the role of HIF-1 in skeletal muscle metabolic adaptive changes as the end-organ in PVD. This review aims to summarize our current understanding of HIF-1 roles and the therapeutic potential in PVD.
Ho
Teik K
TK
Department of Surgery, The Royal Free Hospital, The Royal Free & University College Medical School, London, UK.
Abraham
David J
DJ
Black
Carol M
CM
Baker
Daryll M
DM
D042501:Angiogenic Proteins / Q000235:genetics / Q000378:metabolism / Q000627:therapeutic use; D000818:Animals; D015687:Cell Hypoxia; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D051793:Hypoxia-Inducible Factor 1 / Q000235:genetics / Q000378:metabolism*; D007502:Iron Chelating Agents / Q000494:pharmacology / Q000627:therapeutic use; D007511:Ischemia / Q000209:etiology / Q000235:genetics / Q000378:metabolism* / Q000503:physiopathology / Q000628:therapy; D035002:Lower Extremity / Q000098:blood supply*; D018482:Muscle, Skeletal / Q000098:blood supply* / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D018919:Neovascularization, Physiologic / Q000187:drug effects / Q000235:genetics; D010100:Oxygen / Q000378:metabolism; D016491:Peripheral Vascular Diseases / Q000150:complications* / Q000235:genetics / Q000378:metabolism / Q000503:physiopathology / Q000628:therapy; D011393:Procollagen-Proline Dioxygenase / Q000037:antagonists & inhibitors / Q000378:metabolism; D015533:Transcriptional Activation
D042501:Angiogenic Proteins; D004791:Enzyme Inhibitors; D051793:Hypoxia-Inducible Factor 1; D007502:Iron Chelating Agents; D011393:Procollagen-Proline Dioxygenase; D010100:Oxygen